Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular CarcinomaDigestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasmRecruitingPhase 22026-03-16NCT05528952

3 results · Page 1 of 1

Swipe the table sideways for more columns.

14 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Centre Georges François LeclercDijonFrance35
Centre Hospitalier Paris St JosephParisFrance1
CH de MulhouseMulhouseFrance3
CH William MoreyChalon-sur-SaôneFrance1
CHU de BesançonBesançonFrance26
CHU de MontpellierMontpellierFrance48
CHU de PoitiersPoitiersFrance40
Groupe Hospitalier Paris SalpetrièreParisFrance1
Hôpital BeaujonParisFrance5
Hôpital Henri MondorCréteilFrance27
Hôpital Nord Franche-ComtéMontbéliardFrance5
Hôpital Paul BrousseVillejuifFrance11
Institut de Cancérologie de l'OuestNantesFrance5
Institut Mutualiste MontsourisParisFrance29